IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

SHANGHAI and SOUTH SAN FRANCISCO, Calif., Sept. 7, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, presented initial data from Hengrui's Phase 1 clinical trial of IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate (ADC), in an oral presentation today at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. The presentation included data from a total of 100 patients who received IDE849 at doses between 0.8 mg/kg to 4.2 mg/kg with a once every 3-week dosing interval.

Read more at prnewswire.com